Specifically, we wished to determine whether peptides could support prediction of progression in DKD despite RASi treatment like angiotensin-converting enzyme inhibitor (ACEi) and ARBs (uncontrolled), contrasted by stabilizing kidney function (controlled). Here, ACE is linked to diabetic kidney disease.